Physician profile
Katrina Marie Stringer
NPI 1124409198
$2,517.68
in general payments reported to CMS, 2019-2025
40 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $715 · 2024: $1,670 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.70 |
| Education | $352.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $331.89 | 2023-2024 | Cabometyx |
| Astellas Pharma US INC | $282.59 | 2023-2024 | Xtandi, Xospata |
| Astrazeneca Pharmaceuticals LP | $230.10 | 2023-2024 | Calquence, Enhertu, Tagrisso |
| Abbvie INC. | $178.72 | 2024-2025 | |
| Janssen Biotech, INC. | $163.19 | 2023-2024 | Erleada, Akeega, Balversa |
| Merck Sharp & Dohme LLC | $160.52 | 2023-2024 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $112.51 | 2023-2024 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $98.98 | 2024 | Alunbrig, Ninlaro, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $81.77 | 2024-2025 | |
| Daiichi Sankyo INC. | $79.62 | 2023-2024 | Enhertu, Vanflyta |
| Beigene USA, INC. | $79.51 | 2024 | Brukinsa, Tevimbra |
| Incyte Corporation | $56.71 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Glaxosmithkline, LLC. | $47.48 | 2024 | Jemperli, Zejula, Ojjaara |
| Pfizer INC. | $41.12 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.12 | 2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $29.65 | 2024 | |
| Coherus Oncology, INC. | $27.34 | 2024 | |
| Genmab U.S., INC. | $25.68 | 2024 | Epkinly |
| Apellis Pharmaceuticals, INC. | $25.52 | 2024 | Empaveli |
| Spectrum Pharmaceuticals INC. | $24.97 | 2024 | Rolvedon |
| Acrotech Biopharma INC. | $24.43 | 2024 | Beleodaq |
| Novo Nordisk INC | $24.21 | 2025 | Wegovy |
| Aveo Pharmaceuticals, INC. | $23.80 | 2024 | |
| Array Biopharma INC | $23.79 | 2024 | Xalkori, Lorbrena, Braftovi |
| Corcept Therapeutics | $23.67 | 2025 | Korlym |
| Lilly USA, LLC | $23.29 | 2024 | Verzenio, Jaypirca |
| Genentech USA, INC. | $23.20 | 2024 | Itovebi |
| Regeneron Healthcare Solutions, INC. | $23.02 | 2024 | Libtayo |
| Myriad Genetic Laboratories, INC. | $22.51 | 2024 | Myrisk |
| Octapharma USA, INC. | $21.63 | 2024 | Octagam Immune Globulin (Human) |
| Accord Healthcare, INC. | $21.62 | 2024 | |
| Emd Serono, INC. | $20.23 | 2024 | |
| Inspire Medical Systems, INC. | $18.84 | 2025 | Inspire |
| Pharmacosmos Therapeutics INC. | $18.03 | 2024 | Monoferric |
| Agios Pharmaceuticals, INC. | $17.89 | 2024 | Pyrukynd |
| Viatris Specialty LLC | $16.81 | 2025 | Yupelri |
| Ipsen Biopharmaceuticals, INC | $16.76 | 2023 | Tazverik |
| Eisai INC. | $15.20 | 2023 | |
| Mirati Therapeutics, INC. | $15.01 | 2024 | Krazati |
| Puma Biotechnology, INC. | $12.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.